Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 2012, with the announcement issued on December 18, 2012. The filing reports a strategic regulatory milestone in GSK's respiratory development portfolio, specifically regarding a collaboration with Theravance, Inc.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This document is a current report of a material event rather than a financial statement.
Material Changes and Developments
- US Regulatory Submission: GSK and Theravance submitted a New Drug Application (NDA) to the US FDA for UMEC/VI, a once-daily combination of umeclidinium bromide (LAMA) and vilanterol (LABA).
- Proposed Brand Name: The combination medicine is proposed to be marketed as ANORO ELLIPTA.
- Indication: The application seeks approval for the long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.
- Dosage Strengths: The submission includes 62.5/25mcg and 125/25mcg doses.
Outlook, Guidance, and Risks
Future Regulatory Plans:
- Regulatory filings for UMEC/VI are planned for the European Union imminently and in other countries during 2013.
- GSK intends to commence global regulatory submissions for UMEC monotherapy in the ELLIPTA inhaler for COPD patients in 2013.
Portfolio Context: UMEC/VI is part of a broader late-stage respiratory portfolio including fluticasone furoate/vilanterol (RELVAR/BREO), VI monotherapy, and MABA. None of these investigational medicines are currently approved anywhere in the world.
Risks and Contingencies:
- Both GSK and Theravance include standard forward-looking statement disclaimers, noting that actual results may differ materially from projections.
- Key risks include potential clinical study results indicating products are unsafe or ineffective, delays or failure to achieve regulatory approvals, reliance on third-party manufacturers, and collaboration risks.
Investor Verification Checklist
- Verify the status of the NDA submission for ANORO ELLIPTA with the FDA.
- Monitor upcoming regulatory filings in the EU and other jurisdictions scheduled for 2013.
- Review the progress of other assets in the GSK respiratory portfolio, specifically RELVAR/BREO and UMEC monotherapy.
- Assess the commercial partnership terms and revenue-sharing arrangements between GSK and Theravance for these assets.